Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

The Journal of urology

Volumn 173, Issue 6, 2005, Pages 1966-1967

  Walsh, Patrick C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NEOPLASM; ORCHIECTOMY; PALLIATIVE THERAPY; PHYSIOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ANDROGENS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 19444370187     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)60188-7     Document Type: Article

References (0)